An open-label, multicentre safety study of vemurafenib in patients with BRAF(V600)-mutant metastatic melanoma: final analysis and a validated prognostic scoring system

Larkin James; Brown Michael P.; Arance Ana M.; Hauschild Axel; Queirolo Paola; Del Vecchio Michele; Ascierto Paolo A.; Krajsova Ivana; Schachter Jacob; Neyns Bart; Garbe Claus; Sileni Vanna Chiarion; Mandala Mario; Gogas Helen; Espinosa Enrique; Hospers Geke; Lorigan Paul; Nyakas Marta; Guminski Alex; Liszkay Gabriela; Rutkowski Piotr; Miller Wilson Jr.; Donica Margarita; Makrutzki Martina; Blank Christian

首页> 外文期刊>European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) >An open-label, multicentre safety study of vemurafenib in patients with BRAF(V600)-mutant metastatic melanoma: final analysis and a validated prognostic scoring system

【24h】

An open-label, multicentre safety study of vemurafenib in patients with BRAF(V600)-mutant metastatic melanoma: final analysis and a validated prognostic scoring system

机译：BRAF（V600） - 级转移性黑色素瘤患者Vemureafenib的开放式，多期式安全性研究：最终分析和经过验证的预后评分系统

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Background: The oncogenic BRAF inhibitor vemurafenib improves outcomes for patients with advanced BRAF(V600) mutation-positive melanoma compared with cytotoxic chemotherapy. Vemurafenib is now approved for use in this patient population.

机译：背景：癌肠病BRAF抑制剂Vemurafenib为高级BRAF（V600）突变阳性黑色素瘤的患者的结果改善了与细胞毒性化疗相比的患者。 vemurafenib现在批准用于这种患者人口。

著录项

来源
《European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)》 |2019年第2019期|共11页
作者
Larkin James; Brown Michael P.; Arance Ana M.; Hauschild Axel; Queirolo Paola; Del Vecchio Michele; Ascierto Paolo A.; Krajsova Ivana; Schachter Jacob; Neyns Bart; Garbe Claus; Sileni Vanna Chiarion; Mandala Mario; Gogas Helen; Espinosa Enrique; Hospers Geke; Lorigan Paul; Nyakas Marta; Guminski Alex; Liszkay Gabriela; Rutkowski Piotr; Miller Wilson Jr.; Donica Margarita; Makrutzki Martina; Blank Christian;
展开▼
作者单位

Royal Marsden NHS Fdn Trust London England;

Univ South Australia SA Pathol Ctr Canc Biol Canc Clin Trials Unit Royal Adelaide Hosp Adelaide;

Hosp Clin Barcelona Dept Med Oncol Barcelona Spain;

Univ Klinikum Schleswig Holstein Klin Dermatol Venerol &

Allergol Campus Kiel Kiel Germany;

Ist Ric &

Cura Carattere Sci UOC Oncol Med San Martino IST Genoa Italy;

Fdn Ist Ric &

Cura Carattere Sci Ist Nazl Tumori Dept Med Oncol Milan Italy;

Fdn Pascale Ist Nazl Tumori Naples Italy;

Charles Univ Prague Med Fac 1 Univ Hosp Prague Dermatovenerol Klin Prague Czech Republic;

Chaim Sheba Med Ctr Inst Oncol Ramat Gan Israel;

Afdelingshoofd Med Oncol Brussels Belgium;

Univ Med Ctr Dept Dermatol Tubingen Germany;

Ist Oncol Veneto Padua Italy;

Papa Giovanni XXIII Hosp Bergamo Italy;

Univ Athens Athens Greece;

Hosp La Paz Madrid Spain;

Univ Med Ctr Groningen Groningen Netherlands;

Christie NHS Fdn Trust Manchester Lancs England;

Oslo Univ Hosp Oslo Norway;

Univ Sydney Melanoma Inst Australia Royal North Shore Hosp Sydney NSW Australia;

Natl Inst Oncol Dept Dermatooncol Budapest Hungary;

Maria Sklodowska Curie Mem Canc Ctr Inst Oncol Warsaw Poland;

McGill Univ Segal Canc Ctr Montreal PQ Canada;

F Hoffmann La Roche Ltd Basel Switzerland;

F Hoffmann La Roche Ltd Basel Switzerland;

Netherlands Canc Inst Plesmanlaan 121 NL-1066 CX Amsterdam Netherlands;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词
BRAF(V600) mutation; Metastatic melanoma; Vemurafenib; Safety; Prognostic scoring system;

机译：BRAF（v600）突变;转移性黑色素瘤;vemureafenib;安全;预后评分系统;

相似文献

外文文献
中文文献

1. An open-label, multicentre safety study of vemurafenib in patients with BRAF(V600)-mutant metastatic melanoma: final analysis and a validated prognostic scoring system [J] . Larkin James, Brown Michael P., Arance Ana M., European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) . 2019,第期

机译：BRAF（V600） - 级转移性黑色素瘤患者Vemureafenib的开放式，多期式安全性研究：最终分析和经过验证的预后评分系统
2. Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study. [J] . James Larkin, Michele Del Vecchio, Paolo A Ascierto, The lancet oncology . 2014,第4期

机译：维拉非尼治疗BRAF（V600）突变型转移性黑色素瘤患者：一项开放性，多中心，安全性研究。
3. Vemurafenib in Chinese patients with BRAF V600 mutation–positive unresectable or metastatic melanoma: an open-label, multicenter phase I study [J] . Lu Si, Xiaoshi Zhang, Zhen Xu, BMC Cancer . 2018,第1期

机译：维拉非尼在中国BRAF V600突变阳性，不可切除或转移性黑色素瘤患者中的研究：一项开放性，多中心I期研究
4. IMANI-1 TC3WP Single Drug HAART -Proof of Concept Study Pilot Study of the Safety and Efficacy of Kaletra (LPV/r) as Single Drug HAART in HIV+ ARV- Naive Patients - Interim Analysis of Subjects Completing Final 48 Week Data [C] . J.C. Gathe Jr., M. Washington, C. Mayberry International AIDS Conference . 2004

机译：Imani-1 TC3WP单药搭载概念研究试验试验研究Kaletra（LPV / R）作为艾滋病毒+ ARV天真患者单药HAART的安全性和有效性 - 临时分析受试者完成最终的48周数据
5. Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study [O] . G. V. Long, K. T. Flaherty, D. Stroyakovskiy, -1

机译：转移性BRAF V600E / K突变型黑色素瘤患者的达拉非尼联合曲美替尼与达拉非尼单药治疗：一项3期研究的长期生存和安全性分析
6. Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study [O] . G.V. Long, K.T. Flaherty, D. Stroyakovskiy, 2017

机译：Dabrafenib Plus Trametinib对Dabrafenib患者转移BRAF V600E / K-突变体黑素瘤的单一疗法：长期存活和第3期研究的安全分析

An open-label, multicentre safety study of vemurafenib in patients with BRAF(V600)-mutant metastatic melanoma: final analysis and a validated prognostic scoring system

摘要

著录项

相似文献

相关主题

期刊订阅